尿路上皮癌的一例报告及文献复习
A Case Report and Literature Review of Urothelial Carcinoma
摘要: 背景:众所周知,转移性膀胱癌是膀胱癌的晚期表现。临床上一般认为其转移主要通过淋巴管或血液循环进行,但直接浸润直肠并有直肠环形收缩表现的病例却较为少见。病例介绍:本文报告了1例67岁男性,无明显诱因出现大便梗阻,小便失禁,行肠镜下取组织活检,病理提示转移性尿路上皮癌可能性大,在我科进行膀胱镜检查 + 膀胱肿瘤活检术,术后病理示高级别浸润性尿路上皮癌,后通过腹腔镜下输尿管皮肤造口术及结肠造口术成功进行手术治疗。结论:晚期转移性膀胱癌的诊断至关重要,患者的初始症状并不一定与泌尿系统相关。充分的辅助检查对明确诊断以及制定完善的诊疗方案具有很大的帮助。
Abstract: Background: It is well known that metastatic bladder cancer represents an advanced stage of the disease. Clinically, metastasis is generally considered to occur via lymphatic or hematogenous dissemination; however, cases demonstrating direct rectal invasion with annular rectal stricture are relatively rare. Case Presentation: This article reports a 67-year-old male who developed bowel obstruction and urinary incontinence without obvious predisposing factors. Colonoscopic biopsy suggested a high probability of metastatic urothelial carcinoma. Subsequent cystoscopy with bladder tumor biopsy in our department revealed high-grade invasive urothelial carcinoma on pathological examination. The patient successfully underwent laparoscopic ureterocutaneostomy and colostomy. Conclusion: Timely diagnosis of advanced metastatic bladder cancer is critical, as initial symptoms may not be urologically specific. Comprehensive auxiliary examinations are essential for accurate diagnosis and multidisciplinary treatment planning.
文章引用:祁艺新, 刘昌勋, 董大海, 王科, 杨晓坤. 尿路上皮癌的一例报告及文献复习[J]. 临床医学进展, 2025, 15(6): 632-638. https://doi.org/10.12677/acm.2025.1561770

1. 引言

1.1. 研究背景

尿路上皮癌是一种主要起源于泌尿系统上皮组织的恶性肿瘤,包括肾盂、输尿管、膀胱和尿道。膀胱癌是泌尿生殖系统最常见的恶性肿瘤之一,也是最常见的尿路上皮癌类型之一。膀胱癌的发病率在全球恶性肿瘤中排名第9,在男性恶性肿瘤中排名第7 (9.5/10万),在恶性肿瘤死亡率[1]中排名第13。其发病率在我国恶性肿瘤中排名第13位,在泌尿系统肿瘤中排名第1位[2]。膀胱癌可分为非肌层浸润性膀胱癌(Tis, Ta, T1)和肌层浸润性膀胱癌(T2以上)。

临床上大多数膀胱癌患者被诊断为高分化或中分化非肌层浸润性膀胱癌[3],其中约10%最终发展为肌层浸润性膀胱癌或转移性膀胱癌,进展迅速,易复发,预后较差。尽管早期诊断和抗癌干预取得了进展,转移仍然是晚期浸润性膀胱癌死亡的主要原因[4]

1.2. 转移途径

直肠肿瘤多为原发性,通过血液或淋巴途径扩散,极少数直接扩散至邻近器官,其中,直肠浸润(Rectal Invasion)极为罕见,仅占转移病例的1%~2% [5],且多表现为直肠环形狭窄(Annular Rectal Stricture),易被误诊为原发性直肠癌或炎性肠病[6]。本文报告1例转移性膀胱癌,在彻底检查肠梗阻后,经膀胱镜和病理确诊。

Figure 1. Colonoscopic findings: Rectal stenosis with nodular changes

1. 患者肠镜所见,直肠狭窄,伴结节样改变

2. 病例报告

2.1. 临床资料

患者为67岁男性,1天前因排便受阻于我院行结肠镜检查,发现直肠环形狭窄伴结节样改变(见图1)。病理提示转移性尿路上皮癌可能性大(见图5)。行PET-CT检查,膀胱壁明显增厚,代谢轻度增高,SUVmax约3.3,考虑为膀胱肿瘤。留置导尿前伴有尿频、尿急、夜尿约50次,无肉眼血尿,转至我科治疗。患者自诉有高血压病史10年以上,无心脏病和糖尿病。

2.2. 诊疗过程

体检未见异常,体温36.3℃,P:89次/min,R:20次/min,BP:147/87 mmHg。辅助检查结果显示,患者血常规中性粒细胞百分比升高,淋巴细胞百分比降低,提示炎症。尿常规正常,肾功能尿素下降1.63 mmol/L (正常3.6~9.5 mmol/L),电解质钾下降2.87 mmol/L (正常3.5~5.3 mmol/L)。给予注射用哌拉西林n他唑巴坦钠抗炎治疗,以及复方氨基酸注射液氯化钾注射液治疗。盆腔增强CT示患者直肠壁下段增厚,周围间隙模糊,盆腔及腹膜后未见明显肿大淋巴结(见图2)。进一步行高分辨率MR直肠平扫示直肠壁增厚,管腔狭窄(见图3),病灶下缘距肛缘约29 mm。病灶上下缘约94 mm,膀胱壁亦明显增厚,DWI呈高信号,直肠周围仅多发小淋巴结影,DWI呈稍高信号。通过膀胱镜检查和膀胱肿瘤活检确诊。术后病理提示Ki-67 (+, 60%)为高级别浸润性尿路上皮癌。

Figure 2. High-resolution MR scan, annular thickening of rectal wall with bladder wall thickening

2. 直肠高分辨率MR平扫,直肠管壁环形增厚伴有膀胱壁明显增厚

Figure 3. Contrast-enhanced CT, thickening of lower rectal wall with blurred perirectal space and mild bladder wall thickening

3. CT动态增强扫描,直肠下段管壁增厚、周围间隙模糊膀胱壁略增厚

根据患者的临床表现及辅助检查结果,可初步诊断转移性膀胱癌伴直肠浸润。由于患者病情严重,经与患者及家属讨论,手术方式为腹腔镜下根治性膀胱切除结肠造口术(见图4)。术中发现膀胱结节进入腹腔后向腹腔内突出。考虑患者膀胱肿瘤浸润严重,无法切除,行输尿管皮肤瘘及结肠造口术,手术进展顺利。术后4 d,电解质检查示钾2.63 mmol/L,肾功能检查示尿素2.91 mmol/L,尿酸43.1 μmol/L (正常值202~416 μmol/L),给予口服枸橼酸钾溶液、静脉补钾等适当治疗。术后恢复良好。

Figure 4. Endoscopic manifestations of tumors under colonoscopy and cystoscopy. Colonoscopy shows cauliflower-like mass (3 × 4 cm) protruding into rectal lumen, Cystoscopy reveals follicular hyperplasia with bleeding on right bladder wall

4. 结肠镜下观察到多发新生物突入肠腔,较大者约3 × 4 cm,膀胱镜内观察到膀胱内片状滤泡样增生

Figure 5. Pathological findings confirmed that the rectal biopsy was consistent with urothelial carcinoma

5. 病理结果证实直肠活检考虑尿路上皮癌

3. 文献复习

3.1. 膀胱癌直肠浸润的病理机制

膀胱癌直肠浸润的机制尚存争议,主要假说包括:

3.1.1. 直接浸润

肿瘤穿透膀胱后壁侵犯直肠,多见于膀胱三角区或颈部肿瘤[5]

3.1.2. 淋巴扩散

癌细胞经盆腔淋巴管扩散至直肠周围组织,导致环状收缩[7]

3.1.3. 医源性扩散

既往盆腔手术可能促进肿瘤沿筋膜间隙播散[8]。Saitoh等[6]对膀胱癌转移的尸检研究发现,10%存在直肠浸润,但仅7例表现为环状收缩。本例患者无淋巴结肿大及手术史,支持直接浸润机制。

3.2. 诊断策略

3.2.1. 内镜检查

肠镜可直观显示直肠狭窄及肿瘤形态,活检病理是确诊关键[9]

3.2.2. 影像学评估

MRI高分辨率成像可清晰显示直肠壁分层结构及肿瘤浸润深度[10];PET-CT有助于鉴别原发灶与转移灶[11]

3.2.3. 膀胱镜活检

确诊膀胱癌并评估肿瘤分级(WHO 2022标准) [12]

3.2.4. 分子诊断

近年来液体活检技术(如循环肿瘤DNA检测)在转移性尿路上皮癌诊断中显示出重要价值,可辅助判断肿瘤克隆起源及转移途径[13]。本病例虽未进行ctDNA检测,但结合影像学特征与病理结果仍支持直接浸润的诊断。

3.3. 治疗选择

3.3.1. 根治性手术

适用于局部可切除病例,如根治性膀胱切除术联合盆腔淋巴结清扫[14]

3.3.2. 姑息性手术

输尿管皮肤造口术(CU)适用于无法切除的晚期患者,其并发症率低(15% vs. 肠代膀胱术的32%) [15]

3.3.3. 全身治疗

含铂化疗(如GC方案)可延长生存期,免疫检查点抑制剂(如PD-1抑制剂)用于PD-L1高表达患者[16]

3.3.4. 靶向治疗

针对FGFR3突变(约15%转移性尿路上皮癌存在)的厄达替尼(Erdafitinib)已被FDA批准用于二线治疗[17]。本病例虽未行基因检测,但该方案可作为后续系统治疗的潜在选择。

3.3.5. 免疫治疗

PD-1/PD-L1抑制剂(如帕博利珠单抗)在PD-L1高表达患者中客观缓解率达21% [18]。最新KEYNOTE-361研究显示免疫联合化疗可延长无进展生存期[19],建议术后完善PD-L1检测指导辅助治疗。

4. 讨论

浸润性膀胱癌是指膀胱癌达到膀胱肌层深度或以上,病情严重,具有较高的[9]扩散和转移风险。当浸润性膀胱癌发生晚期转移时,常表现为淋巴转移和血行转移,通常转移至肺、肝等部位,极少数可转移至直肠、盆腔等部位,甚至皮肤转移。本文报告了一例由浸润性膀胱癌引起的直肠环形收缩直接进入直肠的病例。

在恶性肿瘤引起的胃肠道梗阻病因中,结直肠癌是最常见的[20]。在泌尿生殖系统领域,直肠梗阻多由前列腺癌[6]的侵袭或转移引起。此外,Saitoh等学者发现在膀胱癌转移的尸检病例中,10%的患者表现为直肠浸润,但只有7例表现为直肠循环收缩[5]

此外,在浸润机制方面,有学者认为直肠环状收缩是由手术沉积[9]引起,也有学者认为是局部肿瘤侵犯膀胱颈或膀胱三角,突破邓氏筋膜包围直肠[10]引起。也有学者推测是癌细胞的侵袭所致。如有学者报道5例膀胱癌侵犯导致直肠环形收缩,这5例患者均表现为直肠侧蒂增厚,但未累及直肠周围脂肪层。因此,作者假设这些癌细胞容易沿着直肠外侧蒂[8]穿透直肠后壁。相反,Takeuchi H等人描述了1例浸润性膀胱癌导致直肠浸润和部分梗阻的患者。患者磁共振成像显示患者左侧闭孔淋巴结肿大,因此笔者推测该病例的癌细胞可能在穿透直肠壁后[16]之前已沿外侧蒂扩散至直肠壁后。在浸润机制方面,术后病理复查显示肿瘤细胞穿透膀胱全层并浸润直肠肌层(见图5),支持直接浸润假说。免疫组化显示GATA3 (+)、CK7 (+)的典型尿路上皮癌表型,而CDX2 (−)排除原发性直肠癌[21]。本例患者盆腔增强CT示盆腔及腹膜后未见明显肿大淋巴结,侧椎弓根未见明显增厚,既往无手术史。因此,与作者的假设相反,我们假设在该病例中,癌症通过直接穿透直肠后壁扩散,但确切机制尚不清楚。

5. 治疗和预后

浸润周围器官的膀胱癌的标准治疗是根治性膀胱切除术、淋巴结清扫和尿道血流调整。然而,在特殊情况下,当膀胱无法切除时,患者的情况需要通过其他方式进行评估。输尿管皮肤造口术(CU)适用于一般情况较差、不能治愈、不能使用肠道的老年患者。研究表明,对于老年和较虚弱的患者,CU是一种更安全的手术选择[20]。该术式具有手术速度快、出血量少、输血率低、需要重症监护时间短、住院时间短等优点。它还表明当死亡率与其他手术相似时,CU术后并发症的发生率较低。在这种情况下,在无法切除膀胱时,输尿管皮造口术是最合适的预后和并发症预防选择。

6. 结论

直肠环形收缩是转移性膀胱癌的一种罕见表现。当浸润性膀胱癌转移至周围器官时,泌尿生殖系统症状可能不明显。当膀胱癌患者主诉大便梗阻,临床检查提示直肠狭窄时,应考虑浸润性膀胱癌导致直肠环形收缩的可能性,并进行全面的体格检查和辅助检查,以确定肿瘤的位置、大小和转移情况。在考虑患者整体情况及家属意见后,选择治疗方案。此外,为了改善患者的预后和延长生存期,手术治疗后通常需要进行全身化疗,并定期随访和检查,以便早期发现肿瘤的复发和转移。

伦理声明

该病例报道已获得病人的知情同意。

作者贡献

祁艺新负责论文的撰写及全部研究工作,刘昌勋、董大海、王科、杨晓坤参与了部分讨论并对论文内容进行了审阅。

NOTES

*通讯作者。

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
[2] Liu, G.X., Liu, P. and Tang, C. (2012) Relationship between NUSAP1 Expression and Lymph Node Metastasis in Bladder Urothelial Carcinoma. Western Medicine, 34, 240-244.
[3] Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article 749.
https://doi.org/10.3390/medicina57080749
[4] Patel, V.G., Oh, W.K. and Galsky, M.D. (2020) Treatment of Muscle‐Invasive and Advanced Bladder Cancer in 2020. CA: A Cancer Journal for Clinicians, 70, 404-423.
https://doi.org/10.3322/caac.21631
[5] Langenstroer, P., Zacharias, A., Almagro, U. and Dewire, D. (1996) Annular Constriction of the Rectum Secondary to Transitional Cell Carcinoma of the Bladder. Urology, 47, 442-444.
https://doi.org/10.1016/s0090-4295(99)80471-3
[6] Saitoh, H., Hida, M., Wakabayashi, T., Iida, T. and Satoh, T. (1982) Metastasis of Urothelial Tumors of the Bladder: Correlation between Sites and Number of Organs Involved. The Tokai Journal of Experimental and Clinical Medicine, 7, 517-526.
[7] Takeuchi, H., Tokuyama, N., Kuroda, I. and Aoyagi, T. (2016) Annular Rectal Constriction Caused by Infiltrating Bladder Cancer: A Case Report. Molecular and Clinical Oncology, 5, 842-844.
https://doi.org/10.3892/mco.2016.1047
[8] Stillwell, T.J., Rife, C.C. and Lieber, M.M. (1989) Bladder Carcinoma Presenting with Rectal Obstruction. Urology, 34, 238-240.
https://doi.org/10.1016/0090-4295(89)90315-4
[9] Ito, Y., Nishimoto, K., Ogata, K. and Fujioka, T. (2008) [Annular Constriction of the Rectum Secondary to Urothelial Carcinoma of the Bladder]. Hinyokika Kiyo, 54, 553-555.
[10] Kobayashi, S., Kato, H., Iijima, K., Kinebuchi, Y., Igawa, Y. and Nishizawa, O. (2006) Annular Rectal Constriction Due to Infiltration by Bladder Cancer. Hinyokika Kiyo, 52, 569-572.
[11] Cathomas, R., Lorch, A., Bruins, H.M., Compérat, E.M., Cowan, N.C., Efstathiou, J.A., et al. (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 81, 95-103.
https://doi.org/10.1016/j.eururo.2021.09.026
[12] Moch, H., Amin, M.B., Berney, D.M., Compérat, E.M., Gill, A.J., Hartmann, A., et al. (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 82, 458-468.
https://doi.org/10.1016/j.eururo.2022.06.016
[13] Christensen, E., Birkenkamp-Demtröder, K., Nordentoft, I., Høyer, S., van der Keur, K., van Kessel, K., et al. (2017) Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 71, 961-969.
https://doi.org/10.1016/j.eururo.2016.12.016
[14] Korkes, F., Fernandes, E., Gushiken, F.A., Glina, F.P.A., Baccaglini, W., Timóteo, F., et al. (2022) Bricker Ileal Conduit Vs. Cutaneous Ureterostomy after Radical Cystectomy for Bladder Cancer: A Systematic Review. International braz j urol, 48, 18-30.
https://doi.org/10.1590/s1677-5538.ibju.2020.0892
[15] Gakis, G., Efstathiou, J., Lerner, S.P., Cookson, M.S., Keegan, K.A., Guru, K.A., et al. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 63, 45-57.
https://doi.org/10.1016/j.eururo.2012.08.009
[16] Powles, T., Park, S.H., Voog, E., Caserta, C., Valderrama, B.P., Gurney, H., et al. (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 383, 1218-1230.
https://doi.org/10.1056/nejmoa2002788
[17] Loriot, Y., Necchi, A., Park, S.H., Garcia-Donas, J., Huddart, R., Burgess, E., et al. (2019) Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 381, 338-348.
https://doi.org/10.1056/nejmoa1817323
[18] Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J., Fong, L., et al. (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376, 1015-1026.
https://doi.org/10.1056/nejmoa1613683
[19] Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S.Y., et al. (2021) KEYNOTE-361 Investigators. Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 931-945.
[20] Fry, D.E., Amin, M. and Harbrecht, P.J. (1979) Rectal Obstruction Secondary to Carcinoma of the Prostate. Annals of Surgery, 189, 488-492.
[21] Miettinen, M., McCue, P.A., Sarlomo-Rikala, M., Rys, J., Czapiewski, P., Wazny, K., et al. (2014) GATA3: A Multi-Specific but Potentially Useful Marker in Surgical Pathology: A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors. American Journal of Surgical Pathology, 38, 13-22.
https://doi.org/10.1097/pas.0b013e3182a0218f